{"id":"NCT01422187","sponsor":"Pfizer","briefTitle":"A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease","officialTitle":"A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2014-05","completion":"2014-09","firstPosted":"2011-08-23","resultsPosted":"2015-12-14","lastUpdate":"2023-04-19"},"enrollment":19,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gaucher Disease"],"interventions":[{"type":"DRUG","name":"Taliglucerase alfa","otherNames":[]}],"arms":[{"label":"Taliglucerase alfa 30 units/kg","type":"EXPERIMENTAL"},{"label":"Taliglucerase alfa 60 units/kg","type":"EXPERIMENTAL"}],"summary":"This is a multi-center trial to further extend the assessment of the safety and efficacy of taliglucerase alfa in adult subjects (â‰¥18 years old) with Gaucher disease who have enrolled in Protocol PB-06-003. Subjects will continue to receive an intravenous (IV) infusion of taliglucerase alfa every two weeks. The duration of treatment will be a maximum of 21 months or until taliglucerase alfa is commercially available to the subject at the discretion of the Sponsor.","primaryOutcome":{"measure":"Spleen Volume","timeFrame":"60 months","effectByArm":[{"arm":"Taliglucerase Alfa 30 Units/kg","deltaMin":2032,"sd":454.9},{"arm":"Taliglucerase Alfa 60 Units/kg","deltaMin":1960,"sd":451.7},{"arm":"Dose Adjusted","deltaMin":2321.7,"sd":679.6}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27499018"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":["NASOPHARYNGITIS","ARTHRALGIA","PHARYNGITIS","HYPOAESTHESIA","BONE PAIN"]}}